Afya Limited Overview
| Attribute | Detail |
|---|---|
| Legal name | Afya Limited |
| Former / predecessor names | Afya Educacional (IPO-era brand). Operating predecessors were NRE Educacional and Medcel. |
| Origin of operations | 1999: first medical school (ITPAC, Tocantins) |
| Incorporation | 22 March 2019, Cayman Islands (exempted company) |
| Registered office | Ugland House, P.O. Box 309, George Town, Grand Cayman KY1-1104 (per the 2026 merger agreement) |
| Operating headquarters | Belo Horizonte, Minas Gerais, Brazil. Press-release datelines moved from Nova Lima, MG to Belo Horizonte during 2025. |
| Brazilian tax ID (CNPJ) | 33.858.154/0001-78 |
| Listings | Nasdaq Global Select: AFYA (Class A common shares). B3: A2FY34 (BDRs). |
| ISIN | KYG011251066 |
| CUSIP | — |
| Fiscal year end | 31 December |
| Employees | 9,680 (FY2023); 9,717 (FY2024); 9,395 (FY2025). Source: FY2025 6-K ESG table. |
| Auditor | confirm against the FY2025 Form 20-F |
| Share count | About 88.5M shares outstanding (aggregator data, 2026) |
| Market capitalisation | About US$1.23bn (88.5M shares × US$13.92 close on 6 Oct 2026). Aggregator range in 2026: US$1.23–1.36bn. |
| Credit rating | Moody's local-scale AAA.br, stable outlook, reaffirmed 5 May 2026 |
| Website | www.afya.com.br; investor relations at ir.afya.com.br |
| Controlling shareholders | Bertelsmann SE & Co. KGaA (through Erste WV Gütersloh GmbH) and the Esteves family, which together form the controlling bloc |
The listed company is Afya Limited, a Cayman Islands exempted company. Its Class A common shares trade on Nasdaq under the ticker AFYA, and its Brazilian Depositary Receipts trade on B3 as A2FY34.
The ISIN supplied in the request (KYG011251066) belongs to this issuer. The listing has not moved and the entity has not been renamed.
On 23 September 2026 Afya signed a binding agreement to merge into YDUQS Participações S.A. (B3: YDUQ3). On completion:
-
Afya would cease to exist as a separate legal entity.
-
Afya would be delisted from Nasdaq.
-
Afya shareholders would receive newly issued YDUQS shares and hold 69% of the combined company.
The transaction is pending. It still needs approval from CADE (Brazil's antitrust authority) and from both companies' shareholders.
Afya is Brazil's largest private medical-education group by number of authorised medical-school seats. It had 3,768 operating seats at mid-2026, roughly 10–11% of private seats nationally.
Around that licence-protected undergraduate core it has built a "physician-centric ecosystem". This ecosystem follows a doctor from medical school through:
-
residency preparation;
-
specialist and graduate programmes;
-
digital clinical-decision tools (Afya Whitebook);
-
practice-management software (Afya iClinic).
Brazil's federal government tightly rations medical seats through its Ministry of Education, MEC, and the Mais Médicos programme. That scarcity gives the core business strong pricing power:
-
The medical-school net ticket was about R$9,443 per student per month in 1H26.
-
The business has very high occupancy.
-
Adjusted EBITDA margins have run in the low-to-mid 40s.
In FY2025 Afya generated R$3.70bn of revenue and R$1.68bn of adjusted EBITDA, and has met or exceeded guidance every year since 2H19. Its strategic identity is now in transition. The pending all-share merger into YDUQS would fold Afya into a diversified Brazilian higher-education group in which medicine represents about 45% of revenue. Bertelsmann would remain the anchor shareholder, and Afya's CEO would lead the combined company.
Company self-description (paraphrased from the 2026 6-K boilerplate)
Afya describes itself as Brazil's leading medical education group by number of medical-school seats. It frames itself as an end-to-end ecosystem that serves physicians across their whole career:
-
as medical students;
-
through residency preparation and graduate programmes;
-
through continuing medical education;
-
through medical-practice solutions that help doctors run their practices.
Reporting segments (latest definitions, 2Q26 6-K)
-
Undergraduate. Formerly called "Undergrad". It covers undergraduate degrees in medicine, other health sciences and non-health programmes.
-
Continuing Education. This covers residency-preparation programmes, specialisation-exam preparation, other medical capability courses, and specialisation and graduate courses in medicine. Delivery is digital and in-person.
-
Medical Practice Solutions (MPS). This covers clinical-decision tools, clinical (practice) management and doctor–patient relationship tools. It also provides access, demand-generation and efficiency services to healthcare players such as pharmaceutical companies.
Revenue model
| Revenue type | FY2025 (BRL Mn) | Share of gross segment revenue | Character |
|---|---|---|---|
| Undergraduate tuition | 3,255.4 | 87.7% | Monthly tuition fees, recognised over the semester. Driven by occupancy, seat maturation and ticket. |
| Continuing Education | 284.5 | 7.7% | Mostly monthly tuition from business-to-physician (B2P) customers. The residency-journey product includes e-books recognised at a point in time, which concentrates revenue in Q1 and Q4. Business-to-business (B2B) revenue was R$26.8M. |
| Medical Practice Solutions | 171.3 | 4.6% | Subscription/SaaS from physicians (Whitebook, iClinic, Shosp), R$152.6M, plus B2B pharma and healthcare solutions, R$18.7M |
| Inter-segment eliminations | -14.0 | — | — |
Revenue is overwhelmingly recurring tuition.
Source: FY2025 6-K. Shares are computed on gross segment revenue before eliminations.
By model type, about 95% of revenue is service or tuition revenue that behaves like a subscription. About 4% is SaaS or app subscription. B2B and advertising-style revenue is about 1%. Product sales are immaterial apart from e-books inside Continuing Education.
Value-chain position and customers
Afya sits at the start of the physician supply chain, where it has unusual pricing power.
Undergraduate customers: are students and their families. Fees are financed:
-
privately, in most cases;
-
through FIES (federal student financing);
-
through ProUni (tax-incentive scholarships). In FY2025, 16,148 students were on FIES or ProUni, equal to 18.8% of undergraduates (FY2025 6-K ESG table).
Continuing Education and MPS customers: are practising physicians (B2P) and pharmaceutical companies, hospitals, labs and other healthcare players (B2B).
End-markets: - Brazilian private higher education in medicine and health;
-
post-graduate medical education;
-
Brazilian health-IT for physicians (clinical decision support, EMR and practice management).
Independent characterisation
Economically, Afya is a regulated-scarcity asset with a digital option attached.
The undergraduate medical business generates almost all profit and cash:
-
1H26 medical-school revenue of R$1,499.4M was 76% of the R$1,984.8M group total.
-
Seat licences are hard to obtain.
-
Demand for medical places far exceeds supply.
-
Tuition is high and inflation-linked.
The "ecosystem" segments have grown more slowly than management once projected:
-
MPS revenue grew 5.9% in FY2025.
-
Total MPS monthly active users fell 7.7% in FY2025 and a further 7.9% year on year in 1H26.
In 2026 management launched an "investment cycle" to deepen physician engagement, which is compressing margins. Separately, the ENAMED national medical-graduate exam has introduced quality-linked seat sanctions. The underlying thesis has therefore shifted from "scarcity forever" to "scarcity, subject to quality compliance."
Strategy
Stated strategy, paraphrased from the FY2025 and 2Q26 6-Ks
Brand ambition: Management describes 2026 as a "new phase" in which Afya aims to be the go-to brand for every Brazilian physician at every career stage.
2026 investment cycle: The plan is to widen Afya's audience, strengthen its digital products and deepen engagement. The goal is to grow the physician base and keep undergraduate student acquisition costs structurally low. Management also sees this as building a platform for future B2B revenue.
Undergraduate: The focus is on maturing seats, applying ticket discipline and running a unified national intake for medicine. Health sciences are growing as a diversification lever: students rose 18% in 1H26.
Capital allocation: M&A is pursued only when returns clear internal thresholds. Excess capital is returned through dividends (40% of FY2025 net income) and buybacks.
Return framing: Management argues that an 11% LTM FCFE yield plus 13% EPS growth implies about 24% potential annual equity return at a constant multiple.
Strategic initiatives, last 24 months
| Initiative | Date | Description / targets | Status |
|---|---|---|---|
| Merger with YDUQS | Talks confirmed about 24 Aug 2026; signed 23 Sep 2026 | All-share merger with a 69/31 split. Synergy NPV of R$2.0–2.2bn, about 80% captured within three years. Pro-forma leverage falls from 1.6x to 1.2x. Expected close within about 12 months; long-stop date 31 Mar 2028. | Pending: CADE review and shareholder votes |
| 2026 ecosystem investment cycle | Announced Mar 2026 | Higher payroll, sales and marketing spending in Continuing Education and MPS. Capex guidance rises to R$340–380M, from R$304M ex-licences in FY2025. | In execution; margin dilutive |
| Liability management | Oct–Nov 2025 | R$1.5bn notes issued; SoftBank facility and preferred shares retired; duration extended to 3.6–3.7 years | Completed |
| Shareholder remuneration | Mar 2025 onward | First dividend (20% of FY2024 net income); FY2025 dividend raised to 40%; 4.0M-share buyback through Dec 2026, of which about 60% remained in March 2026 and 2.7M shares were repurchased in 1H26 | Ongoing |
| Unified medical-school intake | 2025–26 | A single admissions process across all medical schools | Operating |
| Seat expansion via MEC authorisations | 2025–26 | Bragança +100, Pato Branco +2, Abaetetuba +63 (with Cametá relinquished) | Completed |
| ENAMED response | 2,026 | Afya filed appeals with INEP over its 2025 results. The next ENAMED edition was expected in October 2026. | Ongoing |
| ESG programme | Ongoing | Quarterly ESG KPIs; own solar generation; free consultations | Ongoing |
Medium-term financial targets
Management issues only one-year guidance. For FY2026 that is revenue of R$3,950–4,100M, adjusted EBITDA of R$1,700–1,800M and capex of R$340–380M. Medium-term targets are not publicly disclosed. The merger documentation implicitly replaces any standalone long-term plan with combined-company synergy targets.
Products & Services
Undergraduate segment
| Offering | Description | Target customer | Scale / metric | Pricing model |
|---|---|---|---|---|
| Afya medical schools (MD degree, six years) | On-campus undergraduate medicine across the network. Legacy brands include ITPAC, UNIPTAN, UniRedentor, Unigranrio, FESAR, FCMPB, Santo Agostinho, UNIFIPMoc, FIP Guanambi, Garanhuns, UNIDOM and FUNIC; units are increasingly branded "Afya". | Secondary-school graduates and career changers | 3,768 operating seats (2026); 26,421 students (1H26) | Monthly tuition. Net average ticket was R$9,443/month in 1H26, up 3.9%. |
| Unified intake process | A single national admission process across all Afya medical schools, launched before 2026. Described by management as a key enabler of candidate quality and efficiency. | Medical applicants | Not quantified | — |
| Undergraduate health sciences | Dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, biomedicine | Health-career students | 30,350 students (1H26), up 18% | Monthly tuition (ticket not disclosed) |
| Other non-health undergraduate | Business administration, accounting, law, civil and industrial engineering, and others | General higher-education students | 37,367 students (1H26) | Monthly tuition |
| Free clinical services (social mission) | Free clinical consultations delivered by students and clinics | Local communities | 897,793 consultations (FY2025) | Free |
Continuing Education segment
| Offering | Description | Target customer | Metric | Pricing |
|---|---|---|---|---|
| Afya Residency Journey (heritage brand Medcel) | Residency-exam preparation, mostly online, including e-books and question banks | Final-year students and graduates | 9,244 students (1H26); 12,990 at FY2025 end, down 20.7% YoY | Course fees plus e-books recognised at a point in time |
| Afya Graduate Journey (heritage brand IPEMED) | Medical specialisation and graduate programmes, delivered in-person and hybrid | Practising physicians | 10,213 students (1H26), up 12.8% | Monthly tuition |
| Other courses (B2P) | Short-term programmes and capability courses. Includes content from the Além da Medicina, Cardiopapers and Medical Harbour acquisitions (integration status not fully disclosed). | Physicians | Part of 36,780 "other" students | Lower ticket per student |
| Continuing Education B2B | Training programmes for institutions | Hospitals, healthcare companies | B2B revenue R$26.8M (FY2025); R$9.1M in 1H26, down 25.4% | Contracts |
Medical Practice Solutions segment
| Offering | Description | Target customer | Metric | Pricing |
|---|---|---|---|---|
| Afya Whitebook (from PEBMED, acquired 2020) | Mobile and web clinical-decision app with drug references, protocols and calculators | Physicians and medical students | 150,048 Clinical Decision active payers (1H26), down 5.9% | Subscription |
| Afya iClinic (acquired 2021) | Cloud practice-management software and electronic medical records, with telemedicine and digital-prescription features | Physicians in private practice | Part of 50,499 Clinical Management payers, up 20.4% | SaaS subscription |
| Shosp (acquired 2021) | Clinic-management software | Multi-physician clinics | Included in Clinical Management | SaaS (reclassified to B2P in FY2025) |
| Glic (via Quasar, acquired 2022) | Diabetes-management app linking physician and patient | Physicians and patients | — | — |
| Medicinae (acquired 2021) | Financial and receivables services for physicians | Physicians | — | — |
| Cliquefarma (acquired 2021) | Drug-price comparison platform | Patients, pharmacies | — | — |
| RX PRO (acquired 2021) | Pharma demand-generation and medical-representative solutions (B2B) | Pharmaceutical companies | MPS B2B revenue R$18.7M (FY2025), down 16.1% | B2B contracts |
| Afya Papers / Cardiopapers / Medical Harbour content (acquired 2021–22) | Specialty content platforms | Specialists | — | Subscription |
Ecosystem metric
| Metric | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|
| Ecosystem outreach (users) | 301,706 | 303,964 | 300,646 | 303,553 | 294,816 |
| MPS monthly active users | 230,468 | 227,941 | 220,051 | 220,528 | 212,158 |
Source: 2Q26 6-K Table 5. Launch years for products follow their acquisition dates, and Afya does not disclose version histories. Product-level pricing is not publicly disclosed except for the medical-school net ticket.
Financial Narrative
All figures are R$M unless noted. FY2021–22 come from the 4Q22 6-K, FY2023–25 from the FY2025 6-K, which shows audited FY2023–24 and unaudited FY2025. LTM 2Q26 figures are computed from the 2Q26 6-K.
Income statement
Notes on the income statement:
-
The FY2024 dividend was 20% of net income, about R$130M (computed).
-
The FY2025 dividend is R$3.446838 per share (R$307.4M), declared on 12 March 2026.
-
FY2021–22 adjusted EBITDA margins are calculated on adjusted net revenue, which excludes COVID-era mandatory tuition discounts.
Margins and growth (computed)
The revenue CAGR from FY2021 to FY2025 on reported revenue is 21.1% (computed). Organic growth ex-acquisitions was 9.2% in FY2025 and 12.7% in FY2024.
LTM and 2026 run-rate
FY2026 guidance excludes acquisitions completed after the guidance was issued:
-
Revenue: R$3,950–4,100M.
-
Adjusted EBITDA: R$1,700–1,800M.
-
Capex: R$340–380M.
The company reaffirmed this guidance on 13 August 2026.
Balance sheet
Notes:
-
FY2021 cash is derived from the FY2022 cash balance and its disclosed 46.0% YoY increase.
-
FY2022 gross debt and seller payables come from the 4Q22 cost-of-debt table.
-
At 30 June 2026: cash R$1,006.5M; loans R$2,047.9M (R$126.4M current, R$1,921.5M non-current); seller payables R$352.5M; net debt ex-IFRS 16 R$1,394.0M; lease liabilities R$1,070.3M; total assets R$9,326.6M; equity R$4,928.8M; treasury shares R$410.4M.
Cash flow
Notes:
-
The company reported its own FY2025 "Free Cash Flow" of R$1,056M using a different definition.
-
Reported capex including licences was R$404.0M in FY2025 and R$392.6M in FY2024.
-
In 1H26: OCF R$797.8M; dividends paid R$314.9M; buybacks R$133.0M (2.7M shares); company-defined free cash flow to equity R$423.4M. Payout was 105.8% of FCFE.
Ratios (computed from reported figures)
A traditional cash conversion cycle is not meaningful for Afya because it carries no material inventory. Receivable days are shown instead. Current trade receivables rose to R$819.7M at 2Q26 from R$717.4M at year-end 2025, which is partly seasonal.
Commentary on trends, inflections and drivers
Growth phases
2019–2023: acquisition-led hypergrowth: Reported revenue rose from R$1.72bn in FY2021 to R$2.88bn in FY2023. Revenue grew 35.5% in FY2022, but only about 18.5% of that was organic. Key acquisitions were Unigranrio in 2021, FIPMoc and Guanambi in 2021, DelRey in January 2023, and a string of digital deals.
Adjusted EBITDA margins fell from 43.1% in FY2021 to 40.6% in FY2023, for three reasons:
-
integration drag;
-
start-up losses on the new Mais Médicos campuses;
-
Medcel weakness in a more competitive residency-prep market (4Q22 6-K).
FY2024–25: margin inflection and harvest: Margins expanded 360 bps in FY2024 to 44.1% and a further 130 bps in FY2025 to 45.4%. Management cites:
-
higher undergraduate and Continuing Education gross margins;
-
restructuring within Continuing Education and MPS;
-
SG&A efficiency (FY2025 6-K).
Operating margin rose from 26.7% to 32.8% over FY2023–25. Net income grew 60.1% in FY2024 and 18.4% in FY2025, helped by lower amortisation of acquired intangibles and a low effective tax rate.
2026: deliberate re-investment: Guidance implies the adjusted EBITDA margin will fall to about 43.5% at the midpoint. Year to date, the 1H26 margin of 46.2% was 190 bps lower year on year, and the 2Q26 margin of 41.8% was 180 bps lower.
Revenue growth has also slowed:
-
1H26: +7.0%.
-
2Q26: +5.7%.
The organic drivers have narrowed to medical-ticket increases (+3.9%) and seat maturation, with medical student growth of only +2.7% year on year.
Taxation
FY2025 tax expense rose to R$92.5M from R$27.5M. The effective rate was 10.7%, versus 4.1%. The rise reflects an additional CSLL (social contribution) provision under Brazil's implementation of the OECD Pillar Two global minimum tax, partly offset by recognition of deferred tax assets.
In 2Q26 the effective tax rate fell to about 1%. Management cites a "tax impact" from Pillar Two implementation, and a non-current income-tax payable of R$50.0M appeared on the balance sheet.
Tax volatility is therefore a live issue for EPS forecasting. It is also central to the YDUQS deal, because analysts flagged higher income-tax exposure at YDUQS.
Deleveraging and liability management
Net debt ex-IFRS 16 fell from R$1,814.9M to R$1,369.5M during FY2025, despite the FUNIC acquisition, dividends and buybacks. Leverage fell from 1.2x to 0.8x.
The October 2025 R$1.5bn notes refinanced the cheap SoftBank facility:
-
The SoftBank facility cost 5.6% per year, or 40% of CDI.
-
The new notes pay CDI + 0.70% (R$500M, due October 2028) and CDI + 0.85% (R$1,000M, due October 2030).
-
Average duration lengthened from 2.4 to 3.6 years. At 2Q26 it was 3.7 years.
The trade-off is cost. Average cost of debt rose to 15.1% per year in 1H26, from 12.7% in 1H25, because the subsidised SoftBank tranche was replaced at market rates. This is why the net finance result has not fallen even as net debt declined.
Cash generation
Operating cash conversion stayed above 90% throughout, apart from 87.8% in 1H26. Simple free cash flow (OCF minus capex) rose from about R$0.8bn in FY2023 to about R$1.17bn in FY2025. Capital allocation has pivoted from M&A to shareholder returns: R$447.9M was returned in 1H26 alone.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment (BRL Mn) | FY2024 | FY2025 |
|---|---|---|
Undergraduate revenue | 2,895.7 | 3,255.4 |
Continuing Education revenue | 255.4 | 284.5 |
Medical Practice Solutions revenue | 161.8 | 171.3 |
Inter-segment eliminations | -8.6 | -14.0 |
Total revenue | 3,304.3 | 3,697.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment growth and mix (%)
| Segment growth and mix (%) | FY2024 | FY2025 |
|---|---|---|
Undergraduate YoY growth (%) | — | 12.4 |
Continuing Education YoY growth (%) | — | 11.4 |
Medical Practice Solutions YoY growth (%) | — | 5.9 |
Undergraduate % of gross segment revenue | 87.4 | 87.7 |
Continuing Education % of gross segment revenue | 7.7 | 7.7 |
Medical Practice Solutions % of gross segment revenue | 4.9 | 4.6 |
Revenue by Segment and Revenue by Segment (BRL)
| Undergraduate sub-line (BRL Mn) | FY2024 | FY2025 |
|---|---|---|
Medical school revenue | 2,477.9 | 2,789.2 |
Health science revenue | 236.8 | 261.7 |
Other non-health undergraduate revenue | 181.0 | 204.5 |
Medical school net avg ticket ex-acquisitions (R$ per month) | 8,809 | 9,060 |
Operating medical seats | 3,543 | 3,705 |
Medical students, end of period | 24,255 | 25,556 |
Revenue by Segment (1H2025–1H2026)
| Segment (BRL Mn) | 1H2025 | 1H2026 |
|---|---|---|
Undergraduate | 1,641.5 | 1,762.2 |
of which Medical school | 1,407.3 | 1,499.4 |
of which Health science | 130.6 | 147.5 |
of which Other undergraduate | 103.5 | 115.3 |
Continuing Education | 137.5 | 143.9 |
Medical Practice Solutions | 84.0 | 85.3 |
Total revenue | 1,855.8 | 1,984.8 |
Revenue by Segment (FY2021–FY2022)
| Legacy segment (BRL Mn) | FY2021 | FY2022 |
|---|---|---|
Undergrad (reported) | 1,498.4 | 2,037.9 |
Continuing Education (legacy) | 73.0 | 108.8 |
Digital Services (legacy) | 152.0 | 190.0 |
Inter-segment | -4.0 | -7.6 |
Total reported net revenue | 1,719.4 | 2,329.1 |
Income Statement and Per-Share Data
| Metric (BRL Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (reported) | 1,719.4 | 2,329.1 | 2,875.9 | 3,304.3 | 3,697.3 |
Adjusted net revenue (FY21–23 non-GAAP) | 1,752.7 | 2,319.1 | 2,874.1 | 3,304.3 | 3,697.3 |
Cost of services | — | — | 1,109.8 | 1,215.6 | 1,313.9 |
Gross profit | — | — | 1,766.1 | 2,088.7 | 2,383.4 |
SG&A | — | — | 940.1 | 1,008.4 | 1,113.1 |
Operating income (EBIT) | — | — | 767.1 | 1,012.1 | 1,213.1 |
Adjusted EBITDA | 754.8 | 961.9 | 1,165.7 | 1,455.6 | 1,680.3 |
Net finance result | — | — | -347.0 | -347.5 | -366.1 |
Pre-tax income | — | — | 429.6 | 676.4 | 860.9 |
Income tax expense | — | — | 24.2 | 27.5 | 92.5 |
Net income | 242.3 | 392.8 | 405.4 | 648.9 | 768.4 |
Net income attributable to owners | — | — | 386.3 | 631.5 | 752.5 |
Adjusted net income | 440.4 | 535.1 | 591.1 | 820.3 | 901.7 |
Basic EPS (BRL) | 2.39 | 4.14 | 4.30 | 7.01 | 8.32 |
Diluted EPS (BRL) | — | — | 4.27 | 6.93 | 8.24 |
Dividends per share declared for the fiscal year (BRL) | 0 | 0 | 0 | — | 3.45 |
Margin Analysis (%)
| Ratio (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY | — | 35.5 | 23.5 | 14.9 | 11.9 |
Gross margin | — | — | 61.4 | 63.2 | 64.5 |
Operating margin | — | — | 26.7 | 30.6 | 32.8 |
Adjusted EBITDA margin (company basis) | 43.1 | 41.5 | 40.6 | 44.1 | 45.4 |
Net margin | 14.1 | 16.9 | 14.1 | 19.6 | 20.8 |
Effective tax rate | — | — | 5.6 | 4.1 | 10.7 |
Income Statement and Margin Analysis (%)
| Metric (BRL Mn) | 1H2025 | 1H2026 | LTM 2Q26 | FY2026 guidance midpoint |
|---|---|---|---|---|
Revenue | 1,855.8 | 1,984.8 | 3,826.3 | 4,025.0 |
Adjusted EBITDA | 892.8 | 918.0 | 1,705.5 | 1,750.0 |
Adjusted EBITDA margin (%) | 48.1 | 46.2 | 44.6 | 43.5 |
Net income | 433.6 | 463.1 | 797.9 | — |
Basic EPS (BRL) | 4.69 | 5.10 | 8.73 | — |
Capex | 225.1 | 120.0 | — | 360.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric (BRL Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | — | — | — | 8,829.5 | 9,357.9 |
Cash and equivalents | 748.7 | 1,093.1 | 553.0 | 911.0 | 1,125.4 |
Loans and financing, current | — | — | — | 363.6 | 60.7 |
Loans and financing, non-current | — | — | — | 1,831.6 | 1,993.6 |
Accounts payable to selling shareholders | — | 528.7 | — | 530.8 | 440.6 |
Gross debt incl. seller payables (ex-leases) | — | 2,473.8 | — | 2,725.9 | 2,494.9 |
Lease liabilities (IFRS 16) | — | — | — | 978.3 | 1,065.7 |
Net debt ex-IFRS 16 | 1,378.9 | 1,380.7 | — | 1,814.9 | 1,369.5 |
Net debt incl. IFRS 16 | — | — | — | 2,793.3 | 2,435.2 |
Intangible assets incl. goodwill | — | — | — | 5,532.8 | 5,588.0 |
Total equity | — | — | — | 4,310.6 | 4,891.2 |
Working capital (current assets minus current liabilities) | — | — | — | 449.6 | 1,058.1 |
Cash Flow and Margin Analysis (%)
| Metric (BRL Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow before income tax paid | 666.6 | 877.0 | 1,088.8 | 1,453.2 | 1,547.6 |
Net cash from operating activities | 630.9 | 843.9 | 1,043.6 | 1,432.7 | 1,531.6 |
Capex, cash (PP&E plus intangibles) | — | 297.0 | 245.4 | 392.6 | 364.0 |
Free cash flow (OCF minus capex, computed) | — | 546.9 | 798.2 | 1,040.1 | 1,167.6 |
Acquisitions of subsidiaries, net of cash | — | 99.4 | 815.0 | 627.6 | 144.1 |
Dividends paid | — | — | 18.8 | 18.3 | 146.8 |
Share buybacks | — | 152.3 | 12.4 | 0.0 | 77.0 |
Operating cash conversion ratio (%) | 100.8 | 94.4 | — | 102.2 | 93.7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, net income / year-end equity (%) | — | — | — | 15.1 | 15.7 |
ROE, net income / average equity (%) | — | — | — | — | 16.7 |
ROA, net income / average assets (%) | — | — | — | — | 8.4 |
ROIC, NOPAT / (equity + net debt ex-IFRS 16) (%) | — | — | — | 15.8 | 17.3 |
Current ratio (x) | — | — | — | 1.39 | 2.20 |
Gross debt / equity, ex-leases (x) | — | — | — | 0.63 | 0.51 |
Net debt ex-IFRS 16 / adjusted EBITDA (x) | 1.8 | 1.4 | — | 1.2 | 0.8 |
Net debt incl. IFRS 16 / adjusted EBITDA (x) | — | — | — | 1.9 | 1.4 |
EBIT / finance expenses (x) | — | — | 1.68 | 2.21 | 2.16 |
Adjusted EBITDA / finance expenses (x) | — | — | 2.55 | 3.17 | 3.00 |
Asset turnover, revenue / average assets (x) | — | — | — | — | 0.41 |
Receivable days, current trade receivables / revenue × 365 | — | — | — | 65.8 | 70.8 |
Revenue by Region and Region Margins & Growth (%)
| Region (BRL Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Brazil revenue | 2,875.9 | 3,304.3 | 3,697.3 |
Rest of world revenue | 0 | 0 | 0 |
Brazil revenue growth (%) | 23.5 | 14.9 | 11.9 |
Share Price and Margin Analysis (%)
| Metric | Oct2021 | Oct2022 | Oct2023 | Oct2024 | Oct2025 | Oct2026 |
|---|---|---|---|---|---|---|
AFYA share price (USD) | 17.45 | 14.74 | 16.10 | 16.76 | 14.17 | 13.92 |
Return, price only (computed) | 1 year | 3 years | 5 years | — | — | — |
AFYA price change (%) | -1.8 | -13.5 | -20.2 | — | — | — |
Valuation Multiples
| Multiple | Afya (LTM 2Q26) |
|---|---|
P/E (x) | 8.0 |
EV/EBITDA, ex-leases (x) | 4.6 |
EV/Sales (x) | 2.0 |
P/B (x) | 1.3 |
Capital Markets
| Item | Detail |
|---|---|
Dividend policy | No fixed policy disclosed. Payout of 20% of FY2024 net income, raised to 40% of FY2025 net income. |
FY2024 dividend | Declared Mar 2025: 20% of FY2024 net income (about R$130M, computed) |
FY2025 dividend | R$307.4M (R$3.446838 per share), declared 12 Mar 2026, paid 6 Apr 2026 in US dollars |
Buybacks | Three programmes completed in 2022 (R$152.3M); R$12.4M in 2023; R$77.0M in 2025; R$133.0M (2.7M shares) in 1H26 under the 4.0M-share programme running to 31 Dec 2026 |
Merger constraints | From 30 Jun 2026, Afya may distribute only its adjusted FCFE plus any top-up. Treasury-share changes outside permitted distributions count as "leakage". |
Credit Ratings
| Agency | Rating | Outlook | Date |
|---|---|---|---|
Moody's (national scale) | AAA.br | Stable | Reaffirmed 5 May 2026 |
Capital Instruments
| Instrument | Amount | Cost | Maturity / duration |
|---|---|---|---|
Commercial notes / debentures | 1,538 | 15.2% per year (106% of CDI) | R$500M due Oct 2028 (CDI + 0.70%); R$1,000M due Oct 2030 (CDI + 0.85%); duration 3.9 years |
IFC loan | 510 | 15.5% per year (108% of CDI) | Duration 2.8 years |
Accounts payable to selling shareholders | 353 | 14.3% per year (100% of CDI) | Duration 4.4 years |
Total | 2,400 | 15.1% per year (106% of CDI) | Average duration 3.7 years |
Analyst Conclusions
Management guidance for FY2026
| Item | FY2026 range | Implied change at midpoint vs FY2025 |
|---|---|---|
| Revenue | R$3,950–4,100M | +8.9% |
| Adjusted EBITDA | R$1,700–1,800M | +4.1% |
| Adjusted EBITDA margin | About 43.5% at midpoint | -190 bps |
| Capex | R$340–380M | — |
Guidance was reaffirmed on 13 August 2026.
The 1H26 run-rate (revenue +7.0%, adjusted EBITDA +2.8%) points to the lower half of the revenue range.
Bull case
-
Merger re-rating and synergies. The combined group would trade on B3, with possible index inclusion and deeper local liquidity. Synergy NPV of R$2.0–2.2bn is equivalent to about 21% upside for Afya holders if fully realised (Itaú BBA). Pro-forma leverage would fall to 1.2x.
-
Cash yield. LTM FCFE yield is about 11%, EPS growth was 18.7% in FY2025, and payout was 106% of 1H26 FCFE. On management's framing that implies about 24% potential annual equity return.
-
Scarcity value. Seats change hands at about R$1.8M each in M&A. Afya's 3,768 seats alone would exceed its enterprise value at those prices, which suggests the market is pricing in material ENAMED or regulatory discounting.
Bear case
-
Unfavourable deal terms. The exchange ratio favours YDUQS holders by about 6% (JPMorgan, Itaú BBA). YDUQS's R$750M pre-closing dividend is equivalent to about a 38% yield on YDUQS's own market value. US retail holders face a forced cash-out at B3 prices.
-
ENAMED escalation. Several courses already face sanctions. A poor October 2026 ENAMED result could turn temporary measures into permanent seat losses, directly eroding the core profit pool.
-
Ecosystem thesis fading. MPS monthly active users are falling, Residency Journey students fell 20.7%, and 2026 margins are compressing through investment with no disclosed payback metrics.
Key catalysts and monitorables (next 12 months)
-
Content of Afya Day 2026 (20 Oct 2026): any update on synergies or targets.
-
3Q26 results (expected November 2026): delivery against FY2026 guidance and the second-semester medical intake.
-
ENAMED 2026 results and any MEC revision of the 2025 sanctions.
-
CADE filing, review timeline (up to about 330 days) and possible divestitures in Ji-Paraná, Rio de Janeiro and Teresina.
-
Dates and vote outcomes for the Afya and YDUQS extraordinary general meetings, including dissenter levels under Section 238.
-
YDUQS's use of its R$750M distribution allowance and any Afya top-up.
-
Pillar Two tax normalisation and the effective tax rate.
-
Final buyback execution under the 4.0M-share programme before 31 Dec 2026.
-
The FY2026 dividend decision (March 2027) within the merger's leakage rules.
-
Nasdaq delisting and SEC deregistration mechanics.
Analyst verdict
Afya enters late 2026 as a fundamentally sound but strategically repositioning asset.
The standalone franchise remains one of the highest-quality education businesses in emerging markets:
-
the largest licensed medical-seat base in a supply-rationed market;
-
adjusted EBITDA margins in the mid-40s;
-
cash conversion above 90%;
-
leverage below 1x;
-
seven straight years of meeting guidance.
These qualities justified a premium to Brazilian education peers for most of its listed life.
Three developments have changed the debate.
First, growth has decelerated to mid-single digits, and management has chosen to reinvest margin into a physician ecosystem whose engagement metrics are not yet improving. Second, ENAMED has turned quality into a direct regulatory variable for seat counts, undermining the assumption that scarcity is permanent. Third, and most decisive, the YDUQS merger converts AFYA from a pure medical-education play into the controlling 69% of a diversified B3-listed group, with medicine at about 45% of revenue, broader non-medical exposure and a higher-tax counterparty.
On the evidence, the exchange ratio is modestly favourable to YDUQS. That cost is likely outweighed if the R$2.0–2.2bn synergy NPV is captured and B3 listing improves liquidity and index eligibility. The deal also crystallises a valuation floor near the agreed ratio, and the shares' recovery from about US$11.8 to about US$13.9 after the JPMorgan upgrade suggests the market is beginning to price this.
The principal residual risks are regulatory: CADE remedies in three overlapping cities, and ENAMED 2026 outcomes on the courses already sanctioned. Execution of a large, cross-border, dual-regime merger also carries tax and dissenter complexity.
On balance, at about 4.6x LTM EV/EBITDA (ex-leases) and about 8x earnings, the shares discount a large share of the regulatory risk while offering roughly an 11% cash yield. The investment case is now best framed as event-driven, with a quality underlying business. Holders should prioritise the ENAMED and CADE milestones over standalone growth metrics through 2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Compensation |
|---|---|---|---|
Virgilio Deloy Capobianco Gibbon | Chief Executive Officer | CEO at least since the July 2019 IPO. Designated CEO of the combined Afya–YDUQS company. | Not individually disclosed (see note) |
Luis André Carpintero Blanco | Chief Financial Officer | CFO since May 2020. Previously CFO of OdontoPrev for about 10 years, and earlier CFO of Tele Centro-Oeste Celular (2000–03). | Not individually disclosed |
Renata Costa Couto | Investor Relations Director | Long-tenured IR lead; was IR contact at the 2019 IPO | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Affiliation | Notes |
|---|---|---|---|
Kay Krafft | Co-Chairman (since May 2022; director since Aug 2021) | Bertelsmann | Founding CEO of Bertelsmann Education Group; former Deloitte partner. Designated Chairman of the combined company. |
Nicolau Carvalho Esteves | Co-Chairman (since May 2022; Chairman Jul 2019–May 2022) | Esteves family (founder) | Orthopaedic surgeon with more than 25 years in education; chaired Afya Brazil from Aug 2016 |
Renato Tavares Esteves | Director (since Jul 2019) | Esteves family | Son of Nicolau Esteves |
Two further Bertelsmann nominees | Directors | Bertelsmann | Names not confirmed in 2026 sources. |
Vanessa Claro Lopes | Independent director; audit committee (since Jul 2019) | Independent | Re-appointed at the 2025 AGM for a two-year term |
Miguel Filisbino Pereira de Paula | Independent director | Independent | Re-appointed at the 2025 AGM |
Marcelo Ken Suhara | Independent director; Audit, Risks & Ethics Committee Chair (since 27 Jul 2026); audit committee financial expert | Independent | Succeeded the late João Paulo Seibel de Faria |
João Paulo Seibel de Faria | Former independent director and Audit Chair (2020–2026) | — | Died in July 2026 |
Major Shareholders
| Holder | Stake | Source / caveat |
|---|---|---|
Bertelsmann (Erste WV Gütersloh GmbH) | About 31% of total shares and about 57.5% of votes after May 2022 (Class B shares carry 10 votes each) | Afya release, 4 May 2022. Press reports say Bertelsmann would hold 47.3% of the combined company after the merger, which implies a materially larger current economic interest than 31%. Unreconciled; verify in the merger documents. |
Esteves family (Nicolau Carvalho Esteves, NRE Capital Ventures Ltd) | About 18% of total shares and about 33% of votes after May 2022 | Same source. Party to the 2026 voting agreement. |
Institutional investors (Class A free float) | Aggregators report about 88% of the free float held by institutions | MarketBeat (aggregator). |
Insiders, excluding the controlling bloc | About 0.8% | Aggregator |
SoftBank (SBLA Holdco) | Exited; preferred shares repurchased 3 Nov 2025 | FY2025 6-K |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs Afya | Comparative data |
|---|---|---|---|
Medical undergraduate | YDUQS (IDOMED / Estácio / Ibmec) | Number 2 in private medical seats; merger counterparty | 2,120 medical seats across 19 schools; about 5.5–6% of private seats. LTM revenue about R$5.6bn (computed: combined R$9.4bn minus Afya's R$3.8bn). |
Medical undergraduate | Ânima Educação (Inspirali medical vertical) | Large listed medical-education player | — |
Medical undergraduate | Cogna Educação (Kroton) | Largest Brazilian education group; smaller medical exposure | — |
Medical undergraduate | Ser Educacional | North/Northeast regional competitor with medical schools | — |
Medical undergraduate | Cruzeiro do Sul Educacional | Diversified group with medical schools | — |
Medical undergraduate | Grupo Tiradentes (UNIT, Sergipe) | Northeast medical schools; sold the DelRey assets to Afya | — |
Medical undergraduate | Federal and state public universities | Free tuition, highly selective; shapes national seat supply | — |
Residency preparation (Continuing Education) | Medway, MedGrupo (Medcurso), Estratégia MED, Sanar, Aristo | Digital-first prep players; Afya cited intensified competition affecting Medcel from 2022 | Private; financials not disclosed |
Medical post-graduate | Hospital-linked schools and specialty societies | Fragmented market | — |
Clinical decision support | UpToDate (Wolters Kluwer), Medscape, local apps | Whitebook leads in Portuguese-language mobile reference | — |
Practice management / EMR | Doctoralia (Docplanner), Feegow, Amplimed, Conexa Saúde | Competing SaaS and telehealth offerings | — |
Digital prescription | Memed and others | Overlaps with iClinic features | — |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Afya FY2025 | YDUQS (LTM Jun-2026, approx.) | Combined (LTM Jun-2026) |
|---|---|---|---|
Revenue (BRL Bn) | 3.70 | 5.6 | 9.4 |
Adjusted EBITDA (BRL Bn) | 1.68 | 1.9 | 3.6 |
Adjusted EBITDA margin (%) | 45.4 | 34 | 38 |
Medical seats | 3,768 | 2,120 | 5,888 |
Recent Developments
Guidance was reaffirmed twice.



